Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (13409)	10/7/2004 3:36:38 PM
From: zeta1961	Read Replies (1) \| Respond to of 52153

Maybe that's a partial explanation for why Edwards took on the Ob/Gyn's Biggest laugh of the day..thanks!.. Zeta

To: Ian@SI who wrote (13409)	10/7/2004 7:34:25 PM
From: Michael Young	Read Replies (1) \| Respond to of 52153

<<Seems that the market is putting a litigation discount into all DRG/BTK related issues. Given that many of those being trashed today don't even have an approved drug, can this beating be viewed as a very optimistic outlook for the emerging biotechs?>> There is no doubt the Vioxx trouble is causing negative sentiment toward the entire sector. But the reality isn't nearly so grim. Vioxx happens to be one of those "perfect storm" scenarios that will hurt Merck for a very long time. I don't think it means increased litigation or approval risk for the entire sector. The biggest impact will be felt for "me too" drugs with even the slightest hint of safety issues - although I guess the "me too" issue is being found increasingly through big pharma. Mike